Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected SAN FRANCISCO, CA / ACCESS Newswire / December 10, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that the U.S. Food and Drug Administration (FDA) has granted renewal of the...Read more
PARSIPPANY, N.J. / Dec 05, 2025 / Business Wire / Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in Europe, Portela...Read more
Newest assay expands TRUFORMA market opportunity by building on endocrinology foundation to address reproductive health in the equine segment ANN ARBOR, MI / ACCESS Newswire / December 4, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the expansion of its TRUFORMA...Read more
Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia® A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals SAN FRANCISCO, CA / ACCESS Newswire / December 2, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX)...Read more
PARSIPPANY, N.J. / Nov 26, 2025 / Business Wire / Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an...Read more
EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First U.S. Food and Drug Administration Emergency Use Authorization (EUA) granted for New World screwworm in cats, reinforcing Elanco's leadership in feline innovation Action reinforces the FDA's commitment to act swiftly against emerging animal health threats Scientific studies...Read more
Successful preliminary discussion with NYSE representatives and potential investors OS Therapies shareholders to receive direct equity participation in new listing 'Shelter Me: Cancer Pioneers' film featuring canine and human patients treated with OST-HER2 receives Anthem Award in the 'Documentary or Film under Awareness Categories, Health' category Company congratulates Disney (NYSE: DIS) for winning the 2025 Daytime Emmy...Read more
PARSIPPANY, N.J. / Nov 19, 2025 / Business Wire / Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer; Rob Polzer, Ph.D., Executive Vice President and President of Research and Development; and Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic), Senior Vice President of...Read more
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID Company completed...Read more
Alloy Partners, Elanco and other corporate partners join forces to develop new venture studio INDIANAPOLIS, Nov. 13, 2025 /PRNewswire/ -- Alloy Partners today announced the launch of OneHealth Studio, a first-of-its-kind venture studio designed specifically to create and scale new companies at the convergence of animal, plant and human health in partnership withElanco Animal Health (NYSE: ELAN). Located in the OneHealth Innovation...Read more
PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025. Product Sales Highlights: During the...Read more
TEANECK, N.J. / Nov 05, 2025 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2025 and its updated financial guidance for the year ending June 30, 2026. Highlights for the three months ended September 30, 2025 (compared to the three months ended September 30, 2024) Net sales of $363.9 million, an increase of $103.5...Read more
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Third Quarter 2025 Financial Results: Revenue of $1,137 million, an increase of 10% year-over-year; 9% organic constant currency growth Reported Net Loss of $34 million, Adjusted Net Income of $94 million Adjusted EBITDA of $198 million; Adjusted EBITDA Margin of 17.5% Reported EPS of $(0.07), Adjusted EPS of $0.19 Net leverage...Read more
Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025 Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025 Revises Full Year 2025...Read more
PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began...Read more
Zomedica posts highest quarterly revenue ever and record year-over-year revenue for 19th straight quarter! ANN ARBOR, MI / ACCESS Newswire / November 4, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30,...Read more
Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. Strong organic revenue growth was supported by IDEXX execution and commercial performance, reflecting benefits from IDEXX's innovation, including over 1,700 IDEXX inVue Dx™ placements. Delivers EPS of $3.40, an increase of 21% as reported and 15% on a comparable basis, including...Read more
Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation PARSIPPANY, N.J. / Nov 03, 2025 / Business Wire / Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal...Read more
TEANECK, N.J. / Oct 30, 2025 / Business Wire / Phibro Animal Health Corporation is proud to announce the national launch of Restoris™ piezoelectric dental gel, a revolutionary dental gel designed to treat and support long-term oral health in dogs with periodontal disease. Developed in collaboration with a leading U.S. dental school and licensed to Phibro, Restoris represents a breakthrough in veterinary dental care, offering a dual...Read more
PARSIPPANY, N.J. / Oct 29, 2025 / Business Wire / Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela...Read more
Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board PARSIPPANY, N.J. / Oct 28, 2025 / Business Wire / Zoetis Inc. (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur...Read more
FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tick (Haemaphysalis longicornis), which is rapidly spreading, now reaching 22 states.i The Companion Animal and Parasite Council tracker shows more than 422,000 cases of Lyme disease in dogs so far this year,ii surpassing the...Read more
EUA to Treat Dogs for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First FDA emergency use authorization (EUA) ever granted for NWS in dogs Action reinforces agency's commitment to providing treatment options for NWS in advance of the fly being detected in the U.S. Published literature showed Credelio may be effective in treating NWS in dogsi Preventing open...Read more
Combining peer-reviewed science, superior comfort, and thoughtful design, the Assisi Loop Lounge expands Zomedica's evidence-based therapeutic portfolio and reinforces Assisi's leadership in targeted tPEMF innovation ANN ARBOR, MI / ACCESS Newswire / October 23, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine...Read more
First long-acting canine anti-nerve growth factor monoclonal antibody therapy administered once every three months Approval marks major milestone in the company’s continued innovation for canine OA pain PARSIPPANY, N.J. / Oct 15, 2025 / Business Wire / Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in dogs. Built on a decade...Read more
Expanded agreement strengthens Zomedica's European presence, broadens product portfolio on the market, and positions the Company to capture growth in the multi-billion-dollar global veterinary diagnostics and therapeutic device markets ANN ARBOR, MI, MI / ACCESS Newswire / October 14, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and...Read more
PARSIPPANY, N.J. / Oct 10, 2025 / Business Wire / Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Based on the CVMP’s positive opinion, the European Commission is expected to issue a...Read more
TEANECK, N.J. / Oct 09, 2025 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset targeting periodontal health in companion animals. This agreement grants Phibro exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma’s proprietary...Read more
Live session on October 24th will showcase how the VETGuardian Monitor enhances patient care, improves workflow efficiency, and expands global market opportunities ANN ARBOR, MI, MI / ACCESS Newswire / October 9, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced...Read more
PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2025. Since the first quarter of 2020, the Company...Read more
WESTBROOK, Maine / Oct 07, 2025 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. “Karen is a highly accomplished...Read more
Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral nutrition and supplementary IV fluids) of approximately 37% SAN FRANCISCO, CA, AL / ACCESS Newswire / October 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided its...Read more
With new label, Dectomax®-CA1 Injectable is the first and only parasite control product with conditional approval to help control economically devastating pest Cochliomyia hominivorax (New World screwworm) PARSIPPANY, N.J. / Sep 30, 2025 / Business Wire / Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for...Read more
The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for use in two expanded access programs, authorized by the U.S. Food and Drug...Read more
PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of...Read more
Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant responder analysis results for crofelemer in the prespecified subgroup of patients with breast cancer from the OnTarget study that were reported at the Multinational Association of Supportive Care in Cancer 2025 Annual Meeting and the 2024 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA / ACCESS...Read more
SAN FRANCISCO, CA / ACCESS Newswire / September 23, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, September 25, 2025 at the Emerging Growth Conference and virtually on Tuesday, September 30, 2025 at the Lytham Partners Fall 2025 Conference. Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth...Read more
First and only in-clinic multiplexed Cobalamin & Folate assay now validated for feline patients ANN ARBOR, MI / ACCESS Newswire / September 23, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the expansion of its TRUFORMA diagnostic platform with the addition...Read more
FDA now concludes "the totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling"i Further evaluation of supplemental scientific data drove this FDA update; data now peer-reviewed and published Real-world success and experiences from dermatologists and general practice veterinarians around the U.S. and the world further demonstrate Zenrelia's...Read more
Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the rapidly growing multi-billion dollar veterinary diagnostics market ANN ARBOR, MI / ACCESS Newswire / September 18, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for...Read more
PARSIPPANY, N.J. / Sep 12, 2025 / Business Wire / Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab), a new monoclonal antibody (mAb) therapy intended for the alleviation of pain associated with osteoarthritis (OA) in cats. Portela Will Be First...Read more
Agreement strengthens Canadian veterinarians' access to Zomedica's advanced therapeutic and monitoring solutions ANN ARBOR, MI / ACCESS Newswire / September 10, 2025 / Zomedica Corp. (OTCQB:ZOMDF), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, announced today that it has expanded its distribution agreement with UXR Inc., a leading Canadian animal health...Read more
Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 5, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which takes place September 8-10, 2025. Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 27th Annual Global Investment...Read more
Strategic partnership with Pioneer Veterinary Products Limited expands Zomedica's presence in the UK veterinary market through distribution of its leading point-of-care solutions ANN ARBOR, MI / ACCESS Newswire / September 3, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced a new...Read more
TEANECK, N.J. / Aug 27, 2025 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5...Read more
As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient by up to 27%; abstract describing results accepted for presentation at upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago SAN FRANCISCO, CA /...Read more
New agreement brings innovative shock wave, tPEMF therapy, monitoring, and bleeding control solutions to more than 2,200 member clinics nationwide ANN ARBOR, MI / ACCESS Newswire / August 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for companion and equine animals, announced today a new strategic partnership with VerticalVet,...Read more
PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2025. Product Sales Highlights: During the...Read more
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was...Read more
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results: Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growth Reported Net Income of $11 million, Adjusted Net Income of $131 million Adjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26 Net...Read more
Zomedica posts record year-over-year revenue for 18th straight quarter! ANN ARBOR, MI / ACCESS Newswire / August 6, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2025. "We are very pleased with the 14% growth...Read more
Reports Revenue of $2.5 Billion, Growing 4%, and Net Income of $718 Million, or $1.61 per Diluted Share, Increasing 15% and 18%, Respectively, on a Reported Basis for Second Quarter 2025 Delivers 8% Organic Operational Growth in Revenue and 10% Organic Operational Growth in Adjusted Net Income for Second Quarter 2025 Reports Adjusted Net Income of $783 Million, or Adjusted Diluted EPS of $1.76, for Second Quarter 2025 Raises Full Year...Read more
Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. Advances IDEXX's innovation agenda and continues strong global commercial execution, resulting in record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ placements. Delivers EPS of $3.63, an increase of 49% as reported, and 17% on a comparable basis, net...Read more
The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the world Launch to begin immediately with product in market before the end of Q3 2025 GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission. This approval by...Read more
12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products RAHWAY, N.J. / Jul 10, 2025 / Business Wire / Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for...Read more
Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization for general diarrhea globally Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved...Read more
WESTBROOK, Maine / Jul 10, 2025 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. “Jay is an accomplished executive who brings...Read more
TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8. 100% virus neutralization against 33 current field isolates.1 Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4 TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines. GREENFIELD, Ind.,...Read more
PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2025. Since the first quarter of 2020, the Company...Read more
As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5% The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a period...Read more
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed study Diarrhea is one of the most common reasons owners bring their dog to the veterinarian...Read more
Intellectual Property Portfolio grows to 221 Patents and 140 Trademarks ANN ARBOR, MI / ACCESS Newswire / June 24, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the issuance of a new patent related to its TRUVIEW microscope and provided an update on the Company's current...Read more
TROY, Mich. / Jun 20, 2025 / Business Wire / ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, announces it has entered into a relationship with one of the world’s leading animal health companies to advance ZIVO’s novel immune-boosting compounds for use in multiple poultry market segments. The collaboration is...Read more
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 18, 2025 at the Emerging Growth Conference. Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference When: Wednesday, June 18, 2025 from 9:40 - 10:10 AM Eastern...Read more
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J. / Jun 12, 2025 / Business Wire / Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway,...Read more
Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind., June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP), paving the way for the product's marketing authorization in the European Union in...Read more
Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious...Read more
Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan Drug Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File...Read more
The Catalyst® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome WESTBROOK, Maine, June 5, 2025 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of...Read more
CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a recent virology study showed its novel,...Read more
Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to share groundbreaking results from field studies based on its patented antiviral compound...Read more
Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board PARSIPPANY, N.J. / May 22, 2025 / Business Wire / Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company’s annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and...Read more
PHM23 was one of a handful of molecules chosen by the university Bird Flu helping PHM23 gain awareness of broad-spectrum activity at a university level BOSTON, MASSACHUSETTS, May 21, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing breakthrough antiviral treatments, announced that the University of Georgia confirmed the antiviral PHM23 was to be included...Read more
The TRUFORMA Platform now has the widest dynamic range (without manual dilution) available either at the Point of Care or from a Reference Lab ANN ARBOR, MI / ACCESS Newswire / May 21, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced an update to one of their fastest growing...Read more
SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company agreed to issue to investors unregistered...Read more
Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats:...Read more
ANN ARBOR, MI / ACCESS Newswire / May 15, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2025. "We are pleased with our performance in the first quarter as we posted record year over year revenue for the 17th...Read more
Kennewick, WA, May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced that the University of Florida Veterinary Hospital has been certified to offer IsoPet® Precision Radionuclide Therapy™—a breakthrough cancer treatment for animals. The University of Florida Veterinary Hospital, a leader in advanced veterinary care and research, is now licensed and equipped to deliver IsoPet® therapy as part of its oncology services....Read more
NEW YORK / May 15, 2025 / Business Wire / OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the launch of OS Animal Health, Inc., a wholly owned subsidiary focused on commercializing OST-HER2 for the treatment of canine osteosarcoma. OST-HER2 market opportunity in canine osteosarcoma exceeds $150 million Recent data...Read more
The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 million and 37% versus net Q4 2024 revenue of $3.5 million Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024 and decreased by approximately 13.5% in Q1 2025 over Q4 2024 REMINDER: Today Jaguar to host...Read more
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales...Read more
WESTBROOK, Maine / May 13, 2025 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live...Read more
Innovative Registry Harnesses Shock Wave Therapy to Advance Non-Drug Equine Asthma Treatment and Drive Evidence-Based Veterinary Care ANN ARBOR, MI / ACCESS Newswire / May 13, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of the Equine Asthma Clinical Registry. This...Read more
LANSING, Mich. / May 13, 2025 / Business Wire / Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that James P. Tobin has chosen to retire from the Company’s Board of Directors, effective May 31, 2025. Mr. Tobin has served on Neogen’s Board since 2016 and currently chairs the Governance and Sustainability Committee and serves on the Audit Committee. James C. Borel, Chair of the Neogen Board...Read more
Merck Animal Health unveils its largest economic development project in recent history RAHWAY, N.J. / May 08, 2025 / Business Wire / Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health’s manufacturing facility in De Soto,...Read more
TEANECK, N.J. / May 07, 2025 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2025, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended March 31, 2025 (compared to the three months ended March 31, 2024) Net sales of $347.8 million, an increase of $84.6 million, or...Read more
Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results: Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growth Reported Net Income of $67 million, Adjusted Net Income of $184 million Adjusted EBITDA of $276 million, or 23.1% of Revenue Reported EPS of $0.13, Adjusted EPS of $0.37 Net leverage ratio of 4.4x Adjusted EBITDA Full Year 2025 Guidance: Raising revenue...Read more
TROY, Mich. / May 06, 2025 / Business Wire / ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO’s proprietary active ingredients in...Read more
Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quarter 2025 Delivers 9% Organic Operational Growth in Revenue and 6% Organic Operational Growth in Adjusted Net Income for First Quarter 2025 Reports Adjusted Net Income of $662 Million, or Adjusted Diluted EPS of $1.48, for First Quarter 2025 Updates...Read more
Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements. Delivers EPS of $2.96, an increase...Read more
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE